Atara Biotherapeutics (NASDAQ:ATRA) issued its earnings results on Thursday. The biotechnology company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.45) by ($0.15), Morningstar.com reports.
Shares of ATRA traded up $0.77 during midday trading on Friday, hitting $13.31. 1,176,658 shares of the company traded hands, compared to its average volume of 945,080. The firm has a 50 day simple moving average of $16.84. Atara Biotherapeutics has a 52 week low of $11.89 and a 52 week high of $43.95. The stock has a market cap of $557.24 million, a PE ratio of -2.53 and a beta of 2.08. The company has a debt-to-equity ratio of 0.05, a quick ratio of 9.96 and a current ratio of 9.96.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,800 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $24.61, for a total transaction of $191,958.00. Following the completion of the transaction, the chief executive officer now owns 332,243 shares of the company’s stock, valued at approximately $8,176,500.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Dobmeier acquired 2,000 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were bought at an average cost of $19.50 per share, with a total value of $39,000.00. Following the acquisition, the director now directly owns 16,000 shares in the company, valued at $312,000. The disclosure for this purchase can be found here. 7.00% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ATRA. FMR LLC boosted its holdings in shares of Atara Biotherapeutics by 21.7% during the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Atara Biotherapeutics by 53.8% during the 1st quarter. JPMorgan Chase & Co. now owns 1,917,903 shares of the biotechnology company’s stock valued at $76,237,000 after buying an additional 671,216 shares in the last quarter. Norges Bank purchased a new stake in shares of Atara Biotherapeutics during the 4th quarter valued at about $20,648,000. Federated Investors Inc. PA raised its position in shares of Atara Biotherapeutics by 47.6% during the 1st quarter. Federated Investors Inc. PA now owns 903,307 shares of the biotechnology company’s stock valued at $35,906,000 after buying an additional 291,207 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Atara Biotherapeutics by 107.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock valued at $16,500,000 after buying an additional 245,832 shares in the last quarter.
ATRA has been the subject of several recent analyst reports. Canaccord Genuity reaffirmed a “buy” rating and issued a $70.00 target price on shares of Atara Biotherapeutics in a report on Monday, July 1st. ValuEngine downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 17th. Wedbush reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Wednesday, May 29th. BidaskClub downgraded shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 9th. Finally, William Blair reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Thursday, May 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $41.33.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: What is the return on assets (ROA) ratio?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.